These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

328 related items for PubMed ID: 22386936

  • 21. Metformin inhibits advanced glycation end products (AGEs)-induced growth and VEGF expression in MCF-7 breast cancer cells by suppressing AGEs receptor expression via AMP-activated protein kinase.
    Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S.
    Horm Metab Res; 2013 May; 45(5):387-90. PubMed ID: 23225247
    [Abstract] [Full Text] [Related]

  • 22. Sitagliptin augments protective effects of GLP-1 against advanced glycation end product receptor axis in endothelial cells.
    Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S.
    Horm Metab Res; 2011 Sep; 43(10):731-4. PubMed ID: 21932180
    [Abstract] [Full Text] [Related]

  • 23. Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation.
    Matsui T, Yamagishi S, Takeuchi M, Ueda S, Fukami K, Okuda S.
    Biochem Biophys Res Commun; 2009 Jul 24; 385(2):269-72. PubMed ID: 19460355
    [Abstract] [Full Text] [Related]

  • 24. The protective effect of Smilax glabra extract on advanced glycation end products-induced endothelial dysfunction in HUVECs via RAGE-ERK1/2-NF-κB pathway.
    Sang HQ, Gu JF, Yuan JR, Zhang MH, Jia XB, Feng L.
    J Ethnopharmacol; 2014 Aug 08; 155(1):785-95. PubMed ID: 24953033
    [Abstract] [Full Text] [Related]

  • 25. Olmesartan blocks advanced glycation end products-induced vcam-1 gene expression in mesangial cells by restoring Angiotensin-converting enzyme 2 level.
    Ishibashi Y, Matsui T, Yamagishi S.
    Horm Metab Res; 2014 Jun 08; 46(6):379-83. PubMed ID: 24297485
    [Abstract] [Full Text] [Related]

  • 26. Extracellular matrix is modulated in advanced glycation end products milieu via a RAGE receptor dependent pathway boosted by transforming growth factor-β1 RAGE.
    Serban AI, Stanca L, Geicu OI, Munteanu MC, Costache M, Dinischiotu A.
    J Diabetes; 2015 Jan 08; 7(1):114-24. PubMed ID: 24666836
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Advanced glycation end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK.
    Tanikawa T, Okada Y, Tanikawa R, Tanaka Y.
    J Vasc Res; 2009 Jan 08; 46(6):572-80. PubMed ID: 19571577
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis.
    Ojima A, Matsui T, Nishino Y, Nakamura N, Yamagishi S.
    Horm Metab Res; 2015 Aug 08; 47(9):686-92. PubMed ID: 25611208
    [Abstract] [Full Text] [Related]

  • 33. PEDF inhibits AGE-induced podocyte apoptosis via PPAR-gamma activation.
    Ishibashi Y, Matsui T, Ohta K, Tanoue R, Takeuchi M, Asanuma K, Fukami K, Okuda S, Nakamura K, Yamagishi S.
    Microvasc Res; 2013 Jan 08; 85():54-8. PubMed ID: 23108227
    [Abstract] [Full Text] [Related]

  • 34. Matrix metalloproteinase-1 of gingival fibroblasts influenced by advanced glycation end products (AGEs) and their association with receptor for AGEs and nuclear factor-κB in gingival connective tissue.
    Yu S, Li H, Ma Y, Fu Y.
    J Periodontol; 2012 Jan 08; 83(1):119-26. PubMed ID: 21563948
    [Abstract] [Full Text] [Related]

  • 35. Dual effect of advanced glycation end products in pancreatic islet apoptosis.
    Costal F, Oliveira E, Raposo A, Machado-Lima A, Peixoto E, Roma L, Santos L, Lopes Faria JB, Carpinelli AR, Giannella-Neto D, Passarelli M, Correa-Giannella ML.
    Diabetes Metab Res Rev; 2013 May 08; 29(4):296-307. PubMed ID: 23315923
    [Abstract] [Full Text] [Related]

  • 36. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE).
    Oldfield MD, Bach LA, Forbes JM, Nikolic-Paterson D, McRobert A, Thallas V, Atkins RC, Osicka T, Jerums G, Cooper ME.
    J Clin Invest; 2001 Dec 08; 108(12):1853-63. PubMed ID: 11748269
    [Abstract] [Full Text] [Related]

  • 37. Advanced glycation end products evoke inflammatory reactions in proximal tubular cells via autocrine production of dipeptidyl peptidase-4.
    Kaifu K, Ueda S, Nakamura N, Matsui T, Yamada-Obara N, Ando R, Kaida Y, Nakata M, Matsukuma-Toyonaga M, Higashimoto Y, Fukami K, Suzuki Y, Okuda S, Yamagishi SI.
    Microvasc Res; 2018 Nov 08; 120():90-93. PubMed ID: 30056058
    [Abstract] [Full Text] [Related]

  • 38. Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone.
    Kume S, Kato S, Yamagishi S, Inagaki Y, Ueda S, Arima N, Okawa T, Kojiro M, Nagata K.
    J Bone Miner Res; 2005 Sep 08; 20(9):1647-58. PubMed ID: 16059636
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy.
    Forbes JM, Thorpe SR, Thallas-Bonke V, Pete J, Thomas MC, Deemer ER, Bassal S, El-Osta A, Long DM, Panagiotopoulos S, Jerums G, Osicka TM, Cooper ME.
    J Am Soc Nephrol; 2005 Aug 08; 16(8):2363-72. PubMed ID: 15930093
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.